相似文献
1
Clinical study of isosorbide mononitrate treatment for angina pectoris in coronary heart disease.
Exp Ther Med. 2013 Apr;5(4):1133-1136. doi: 10.3892/etm.2013.958. Epub 2013 Feb 18.
2
Randomized crossover trial of isosorbide mononitrate (Elantan 20) and slow-release glyceryl trinitrate in the treatment of angina pectoris.
Pharmatherapeutica. 1985;4(6):367-75.
3
Anti-ischemic and anti-anginal effects of controlled-release and conventional isosorbide-5-mononitrate in stable angina pectoris.
Zhonghua Yi Xue Za Zhi (Taipei). 1998 Oct;61(10):577-83.
4
5
Treatment of coronary heart disease with isosorbide mononitrate ('Elantan' 20): a multi-centre study in hospital and general practice.
Curr Med Res Opin. 1984;9(2):96-106. doi: 10.1185/03007998409109566.
6
Comparison of 50-mg and 100-mg sustained-release isosorbide mononitrate in the treatment of stable angina pectoris: effects on quality-of-life indices. Dutch Mononitrate Quality of Life (DUMQOL) Study Group.
Angiology. 1999 Dec;50(12):963-9. doi: 10.1177/000331979905001201.
7
Influence of isosorbide-5-mononitrate on the circadian rhythm of angina pectoris.
Arzneimittelforschung. 1992 Mar;42(3):307-10.
8
Efficacy and safety of controlled-release isosorbide-5-mononitrate in Japanese patients with stable effort angina pectoris.
Int Heart J. 2006 Sep;47(5):695-705. doi: 10.1536/ihj.47.695.
9
Isosorbide-5-mononitrate--effective monotherapy in chronic stable angina.
Z Kardiol. 1985;74 Suppl 4:16-20.
10
A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina.
Int J Cardiol. 1996 Feb;53(2):117-26. doi: 10.1016/0167-5273(95)02531-6.
引用本文的文献
1
Recent advances on endogenous gasotransmitters in inflammatory dermatological disorders.
J Adv Res. 2021 Sep 1;38:261-274. doi: 10.1016/j.jare.2021.08.012. eCollection 2022 May.
2
Chemocatalytic value addition of glucose without carbon-carbon bond cleavage/formation reactions: an overview.
RSC Adv. 2022 Feb 9;12(8):4891-4912. doi: 10.1039/d1ra09196d. eCollection 2022 Feb 3.
本文引用的文献
1
Risk refinement, reclassification, and treatment thresholds in primary prevention of cardiovascular disease: incremental progress but significant gaps remain.
Arch Intern Med. 2010 Sep 27;170(17):1602-3. doi: 10.1001/archinternmed.2010.327.
2
Confounding in air pollution epidemiology: the broader context.
Epidemiology. 2007 Jul;18(4):424-6; discussion 427-8. doi: 10.1097/EDE.0b013e318065c008.
3
Epidemiology. Mounting evidence indicts fine-particle pollution.
Science. 2005 Mar 25;307(5717):1858-61. doi: 10.1126/science.307.5717.1858a.
4
Relative importance of borderline and elevated levels of coronary heart disease risk factors.
Ann Intern Med. 2005 Mar 15;142(6):393-402. doi: 10.7326/0003-4819-142-6-200503150-00005.
5
Air pollution and hospital admissions for cardiovascular disease in Taipei, Taiwan.
Environ Res. 2005 May;98(1):114-9. doi: 10.1016/j.envres.2004.07.005.
6
Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease.
Ann Intern Med. 2004 Jul 20;141(2):137-47. doi: 10.7326/0003-4819-141-2-200407200-00013.
7
Mutation of MEF2A in an inherited disorder with features of coronary artery disease.
Science. 2003 Nov 28;302(5650):1578-81. doi: 10.1126/science.1088477.
8
Prediction of coronary heart disease in middle-aged adults with diabetes.
Diabetes Care. 2003 Oct;26(10):2777-84. doi: 10.2337/diacare.26.10.2777.
9
CD62 expression during thrombus formation.
J Pediatr Hematol Oncol. 2003 Mar;25(3):266-9. doi: 10.1097/00043426-200303000-00017.
10
Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study.
Stroke. 2003 Feb;34(2):413-7. doi: 10.1161/01.str.0000051728.85133.32.
Zotero 插件